Brief: Cingulate Announces Detailed Trial Results From Phase 3 Adult Efficacy And Safety Trial Of CTx-1301 For ADHD

Cingulate

11/09/2023 12:18

Sept 11 (Reuters) - Cingulate Inc  CING.O :
    * CINGULATE ANNOUNCES DETAILED TRIAL RESULTS FROM PHASE 3
ADULT
EFFICACY AND SAFETY TRIAL OF CTX-1301 (DEXMETHYLPHENIDATE) FOR
ADHD
    * CINGULATE INC- CTX-1301 DEMONSTRATED A FAVORABLE SAFETY
PROFILE
IN TRIAL COMPARED TO PLACEBO
    * CINGULATE INC-  PHASE 3 CLINICAL TRIAL PROGRAM FOR
CTX-1301
EXPECTED IN SECOND HALF OF 2024

Source text for Eikon:  ID:nGNX739Qzz 
Further company coverage:  CING.O 

 ((Reuters.Brief@thomsonreuters.com;))